Satellos Bioscience Inc. MSCL.TO
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · satellos.com
Satellos Bioscience Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies to restore muscle repair and regeneration in degenerative muscle diseases. Its lead drug candidate, SAT-3247, is an oral small molecule targeting AAK1, currently in Phase 1/2 clinical trials for Duchenne muscular dystrophy in adults and pediatric patients.
Key ratios
ReturnOnAssets TTM -0.4
ReturnOnAssets 2025 -0.4
ReturnOnAssets 2024 -0.31
ReturnOnAssets 2023 -0.38
ReturnOnEquity TTM -0.66
ReturnOnEquity 2025 -0.66
ReturnOnEquity 2024 -0.55
ReturnOnEquity 2023 -0.72
Recent news
Satellos to Present Clinical Program Updates at ICNMD 2026
2026-06-25 · GlobeNewswire
Satellos Bioscience Announces Results of Annual Meeting of Shareholders
2026-06-17 · GlobeNewswire